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Both P-gp and MRP2 mediate transport of 
Lopinavir, a protease inhibitor 
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ABSTRACT 
Polarized epithelial non-human (canine) cell lines stably transfected with human or murine complementary DNA 
(cDNA) encoding for various efflux transporters (P-gp/MDR1, MRP1, MRP2, and Bcrp1) were used to study 
transepithelial transport of Lopinavir (LVR) and compare results with the MDCKII-Wild type cells. These 
transmembrane proteins cause multidrug resistance by decreasing the total intracellular accumulation of drugs. 
Lopinavir efflux was directional and was completely inhibited by MK-571, a selective MRP family inhibitor in the 
MDCKII-MRP2 cell line. Similarly, LVR efflux was also inhibited by P-gp inhibitors P-gp 4008 and GF120918 in 
the MDCKII-MDR1 cell line. The efflux ratios (Efflux rate/ Influx rate) of LVR in the absence of any efflux 
inhibitors in the MDCK-Wild type, MDCKII-MDR1, MDCKII-MRP1, MDCKII-MRP2 and MDCKII-Bcrp1 cell 
monolayers were 1.32, 4.91, 1.26 and 2.89 respectively. The MDCKII-MDR1 and MDCKII-MRP2 cells have 
significantly increased LVR efflux ratio relative to the parental cells due to the apically directed transport by MDR1 
and MRP2 respectively. The efflux ratios in MRP2 and MDR1 transfected cell lines were close to unity in the 
presence of MK-571 and P-gp 4008 respectively; indicating that LVR efflux by MRP2 and P-gp was completely 
inhibited by their selective inhibitors. MDCKII-MRP1 cells did not exhibit a significant reduction in the LVR efflux 
relative to the parental cells, indicating that LVR is not a good substrate for MRP1. Transport studies across 
MDCKII-Bcrp1 cells indicated that LVR is not transported by Bcrp1 and is not a substrate for this efflux protein. In 
conclusion, this study presents direct evidence that LVR is effluxed by both P-gp and MRP2 which may contribute 
to its poor oral bioavailability and limited penetration into the CNS.  
Keywords: MDCKII-MDR1, MDCKII-MRP2, MDCKII-MRP1, MDCKII-Bcrp1, MDCKII-WT, P-glycoprotein (P-
gp), multidrug resistance protein (MRP), breast cancer resistance protein (BCRP), Lopinavir (LVR), uptake, 
transport, permeability, efflux ratio (ER) 
1. INTRODUCTION
HIV protease inhibitors (PIs) have 
revolutionized the treatment of HIV 
infection (Roberts et al., 1990; Vacca et 
al., 1994; Danner et al., 1995; Kempf et 
al., 1995; Patick et al., 1996). Due to 
limited oral bioavailability and poor 
pharmacokinetics of many of the 
currently available PIs, additional efforts 
have been made to design more potent 
PIs with improved pharmacokinetic 
properties. Lopinavir, an analog of 
ritonavir (RVR) is a potent inhibitor of 
wild type and mutant HIV protease (Ki 
=1.3-28 pM) (Kumar et al., 2004). Its 
molecular formula is: C37H48N4O5, 
and its molecular weight is 628.80. Its 
structural formula is outlined in Fig.1. 
The LVR: RVR combination 
(KALETRA) has been shown to be 
effective in the treatment of HIV 
infection and is approved for clinical use 
(Hurst and Faulds, 2000; Miller, 2000). 
LVR, as such, is extensively metabolized 
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by CYP3A4 and produces low systemic 
availability when administered alone. 
RVR potently inhibits CYP3A4 and is 
used in combination with LVR to 
enhance the systemic exposure of LVR. 
This combination results in LVR 
concentrations that greatly exceed those 
necessary in vitro to inhibit both wild-
type and PI-resistant HIV isolates. (FDA 
– Kaletra Prescribing Information, 
10/06/04, p. 3. Available at: 
http://www.fda.gov/cder/foi/label/2004/2
1226s014, 21251s010lbl.pdf).  The 
current once-a-day prescribed dose for 
KALETRA is a 800mg/200mg (LVR: 
RVR) tablet or 10 ml of 80mg/20 mg 
(LVR: RVR) oral solution which 
contains 42.4% v/v alcohol. The 
advantages of prescribing KALETRA 
over other PIs include once daily dosing 
and evidence of better in-vitro activity 
against HIV. The disadvantages include 
low aqueous solubility of LVR, 
accounting for high amount of alcohol 
present in the liquid dosage form and 
high plasma protein binding (98-99%) at 
steady state. A number of clinically 
important drug interactions have been 
reported with LVR: RVR necessitating 
dosage adjustments of LVR: RVR and/or 
the interacting drugs. Several co 
administered drugs are also 
contraindicated in patients receiving the 
co formulation (Cvetkovic and Goa, 
2003).
The low oral bioavailability of LVR was 
attributed to high first-pass metabolism 
(Kumar et al., 2004).  High first pass 
metabolism can also occur due to 
intestinal efflux which can lead to 
increased exposure time to metabolizing 
enzymes (Wacher et al., 1995; Wacher et 
al., 2001; Katragadda et al., 2005). We 
have hypothesized that the low oral 
bioavailability of LVR and possibly 
limited brain penetration could be in part 
due to efflux of LVR by several efflux 
pumps such as P-gp, MRPs and BCRP 
present on intestinal epithelial and blood 
capillary endothelial cells. A single 
report on the interaction of LVR with P-
gp has been published (Vishnuvardhan et 
al., 2003) which suggests that LVR 
induces P-gp upon long term exposure 
and inhibits P-gp on acute exposure.  
From this report, it appears that LVR is a 
substrate for P-gp but its interactions 
with other adenosine triphosphate- 
binding cassette (ABC) efflux 
transporters such as multidrug-resistance 
related proteins (MRPs) and breast 
cancer resistance protein (BCRP) have 
not yet been investigated. Therefore, it is 
important to delineate quantitatively if 
the efflux transporters can restrict, at 
least in part, the permeation of LVR at 
both the intestinal and blood brain barrier 
(BBB) membranes.
Numerous drug transporters are 
expressed in the human intestine 
epithelial and the brain endothelial cells, 
of which the ABC transporters have been 
extensively characterized. ABC 
transporters comprise one of the largest 
membrane bound protein families. These 
proteins transport substrates against a 
concentration gradient with ATP 
hydrolysis as a driving force across the 
membrane. Based on diverse structural 
characteristics and broad substrate 
specificity, ABC transport proteins alter 
the intracellular concentration of a 
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variety of therapeutically relevant 
compounds and cytotoxic agents. The 
efflux pumps serve as natural defense 
mechanisms, influence bioavailability 
and disposition of various structurally 
unrelated compounds (Hoffmann and 
Kroemer, 2004). P-glycoprotein (P-gp), a 
multiple drug resistant (MDR) gene 
product, is a 170-kDa transmembrane 
protein. It transports a wide range of 
compounds, including anticancer drugs, 
steroids, calcium channel blockers and 
antihistamines (Endicott and Ling, 1989; 
Borst et al., 1993; Germann et al., 1993; 
Borst et al., 2000; Pal and Mitra, 2006). 
P-gp-mediated efflux reduces the 
intracellular accumulation of these 
compounds, thereby diminishing drug 
efficacy. In the case of cytotoxic drugs, 
this leads to enhanced cell survival (Kim 
et al., 1998). P-gp is present on the apical 
membrane of many absorptive epithelial 
and endothelial cells. In the brain, P-gp 
is known to be localized on the subapical 
side of the choroid plexus epithelia , on 
the luminal membrane of brain 
microvessel endothelial cells and on the 
albuminal side of the BBB on adjacent 
astrocyte foot processes (Sakata et al., 
1994; Ohnishi et al., 1995; Schinkel, 
1999; Lin, 2004).  Because of its 
localization and distribution, P-gp limits 
the oral absorption and bioavailability of 
PIs across intestine, brain, testis and 
placenta (Kim et al., 1998; Polli et al., 
1999; Smit et al., 1999; Choo et al., 
2000; Huisman et al., 2001; Huisman et 
al., 2002).
Recent studies have demonstrated that 
the PIs are also substrates for the 
multidrug resistance associated proteins 
(MRPs), belonging to the same ABC 
transporter family (Huisman et al., 2002; 
Bachmeier et al., 2005). MRPs are 190 
kD proteins responsible for transport of 
drugs across lipid membranes from 
inside to outside the cell. The expression 
and localization of MRPs requires 
delineation of drug interactions with 
these efflux transporters. So far, eight 
MRP homologs have been identified for 
ABC proteins, MRP1-8. Human MRP1 
and MRP2 have been known to be 
involved in efflux of many therapeutic 
agents such as antineoplastic agents, 
fluroquinolones and PIs like SQV, RVR 
and IVR (Bakos et al., 2000; Naruhashi 
et al., 2002; Letourneau et al., 2005; Pal 
and Mitra, 2006). MRP1 is a widely 
expressed transporter. When present in 
epithelial cells, this protein is found 
primarily in the basolateral membrane 
(Hipfner et al., 1999). High levels of 
MRP1 are present in the epithelium of 
the choroid plexus (Wijnholds et al., 
2000) and in astrocytes (Decleves et al., 
2000). MRP1 expression is also observed 
in primary cultured bovine brain 
microvessel endothelial cells (Zhang et 
al., 2004) and in rat brain parenchyma 
and microvessels (Regina et al., 1998) . 
However, it has been reported that 
MRP1 does not mediate substantial 
polarized transport of saquinavir (SQV), 
RVR and indinavir (IVR) in MDCKII-
MRP1 cells (Huisman et al., 2002). In 
contrast to MRP1, MRP2 is localized on 
the apical membrane of several epithelia 
(Konig et al., 1999; Miller et al., 2000; 
St-Pierre et al., 2000). Its expression is 
found in liver canaliculi, renal proximal 
tubules, gut enterocytes, 
syncytiotrophoblast cells of the placenta 
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and possibly brain capillaries (Keppler 
and Kartenbeck, 1996; Schaub et al., 
1997; St-Pierre et al., 2000; Zhang et al., 
2000). Functionally it is similar to P-gp 
mediated elimination of toxic 
compounds in gut and placenta (Kruh 
and Belinsky, 2003). In rats, MRP2 
contributes to hepatobiliary, intestinal 
and renal excretion and to the reduction 
of oral availability of its substrates 
(Dietrich et al., 2001; Dietrich et al., 
2001). It has been fairly established that 
MRP2 also effluxes PIs (Huisman et al., 
2002; Williams et al., 2002).
The human breast cancer resistance 
protein (BCRP/MXR) is a relatively new 
ABC efflux transporter, originally cloned 
from drug-selected human cancer cell 
lines and human placenta (Allikmets et 
al., 1998; Miyake et al., 1999; Doyle and 
Ross, 2003). Like P-gp, BCRP confers 
high levels of resistance to 
anthracyclines, mitoxantrone, and the 
camptothecins by enhancing drug efflux 
from the cell to extracellular space 
(Litman et al., 2000; Bates et al., 2001; 
Ejendal and Hrycyna, 2002). In addition 
to its role in inducing drug resistance, 
BCRP actively transports structurally 
diverse organic compounds , conjugated 
or unconjugated, such as estrone-3-
sulfate, 17ȕ-estradiol 17-(ȕ-D-
glucuronide), and methotrexate (Chen et 
al., 2003; Imai et al., 2003; Suzuki et al., 
2003; Volk and Schneider, 2003). BCRP 
is prominently expressed in placental 
syncytiotrophoblasts, in the epithelium 
of the small intestine, and in the liver 
canalicular membrane (Maliepaard et al., 
2001; Doyle and Ross, 2003). In fact, 
BCRP is also expressed in larger 
amounts than P-gp in the intestine 
(Taipalensuu et al., 2001). This strategic 
and substantial tissue localization of 
BCRP implies that it also functions as a 
protective drug efflux pump. A recent 
clinical study has shown that inhibition 
of BCRP significantly increases the oral 
bioavailability of topotecan from 40 to 
97% (Kruijtzer et al., 2002). Thus, BCRP 
also plays a crucial role in determining 
absorption, distribution, and elimination 
of drugs that are substrates for this 
transporter. The expression of a BCRP 
homologue, known as brain multidrug 
resistance protein (BMRP), has also been 
reported in porcine brain capillary 
endothelial cells (Eisenblatter et al., 
2003). Both BCRP and BMRP possess 
one half of the MDR1 P-gp structure 
with only six transmembrane domains 
and one ATP binding domain (Doyle et 
al., 1998). In addition to this structural 
similarity, most known substrates for 
BCRP/BMRP are similar to P-gp (i.e., 
hydrophobic, amphiphilic xenobiotics), 
suggesting that PIs may also interact 
with BCRP/BMRP (Litman et al., 2001; 
Doyle and Ross, 2003). In fact, results 
from a recent study suggest that 
saquinavir, ritonavir and nelfinavir may 
serve as inhibitors of BCRP (Gupta et 
al., 2004). 
Thus, cellular efflux by ABC 
transporters, such as P-gp and MRPs, can 
play an important role in lowering 
intestinal absorption and brain 
penetration of LVR. Because these efflux 
transporters are oriented in the secretory 
(i.e., out of the organ or tissue) direction, 
high efflux will lead to lower net 
absorption for LVR. Sub-therapeutic 
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concentrations of PIs in the sanctuary 
sites like brain, testes and bone-marrow 
may cause persistence of viral infections 
leading to drug resistance (Williams and 
Sinko, 1999). So far, no study has been 
undertaken to determine whether LVR 
interacts with these efflux pumps. 
Therefore, the purpose of this study is to 
assess the affinity of LVR for the efflux 
transporters using a well-defined system 
consisting of polarized non-human 
(canine) MDCKII cells, singly 
transfected with human MDR1, human 
MRP1/MRP2 complementary DNA 
(cDNA) or murine Bcrp1 cDNA and also 
to delineate quantitatively whether efflux 
limits permeation of LVR across 
intestinal and BBB absorptive cells.
2. MATERIALS AND METHODS 
2.1. MATERIALS 
Unlabeled (ulb) Lopinavir, 
Fumitremorgin-C and GF120918 were 
generous gifts from Abbott Laboratories 
Inc; National Institutes of Health AIDS 
Research and Reference Reagent 
Program (National Institutes of Health, 
Bethesda, MD) and GlaxoSmithKline 
Ltd respectively. [3H] Lopinavir 
(1Ci/mmol) and [3H] Mitoxantrone 
(4Ci/mmol) were purchased from 
Moravek Biochemicals (Brea, CA, 
USA). P-gp 4008 and MK-571 were 
purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and Biomol 
(Plymouth meeting, PA, USA) 
respectively. High-performance liquid 
chromatography grade DMSO and 
methanol were obtained from Fisher 
Scientific Co. (Pittsburgh, PA, USA) and 
were used as solvents for preparing stock 
solutions of all drugs and inhibitors. 
Trypsin-EDTA solution, Dulbecco’s 
modified Eagle’s medium (DMEM), 
Ham’s F-10 medium and Minimum 
Essential Medium (MEM) were obtained 
from Invitrogen (Carlsbad, CA, USA) 
and fetal bovine serum (FBS) was 
obtained from Atlanta biologicals 
(Lawrenceville, GA, USA) respectively. 
Transwell plates were procured from 
Corning Costar Corp (Cambridge, MA, 
USA). All other chemicals were 
commercial products of reagent or 
enzymatic grade and were obtained from 
Fisher Scientific or Sigma Chemicals. 
2.2. METHODS 
2.2.1. CELL CULTURE
Studies were performed with wild-type 
Madin-Darby canine kidney cells type II 
(MDCKII/WT, a well-characterized, 
polarized epithelial cell line) and stable 
MDCKII transfectants overexpressing 
hMRP1 (MDCKII-MRP1 cells), hMRP2 
(MDCKII-MRP2 cells), hP-gp/MDR1 
(MDCKII-MDR1 cells) and murine 
Bcrp1 (MDCKII-Bcrp1 cells) 
(generously provided by Drs. A. 
Schinkel and P. Borst, The Netherlands 
Cancer Institute, Amsterdam). These cell 
lines were selected as these were the first 
known polarized epithelial cells that 
stably express these transporters, 
enabling direct comparison of their 
functional behaviors without the 
confounding effects of multiple 
transporters expressed in cell lines such 
as Caco-2 (Evers et al., 1997; Evers et 
al., 1998; Kool et al., 1999; Evers et al., 
2000; Jonker et al., 2000; Wijnholds et 
al., 2000). Studies were performed with 
the following cell passage numbers from 
our initial stock: MDCKII-WT (passages 
BothPͲgpandMRP2mediatetransportofLopinavir,aproteaseinhibitor

30 to 40), MDCKII-MRP1 (passages 5 to 
25), MDCKII-MRP2 (passages 5 to 25), 
MDCKII-MDR1 (passages 5 to 15) and 
MDCKII-Bcrp1 (passages 1-5). MDCKII 
cell lines were cultured in T-75 flasks 
with DMEM (with high glucose and 
glutamine concentrations) supplemented 
with 10% FBS, 1% nonessential amino 
acids, penicillin 100 µg/ml and 
streptomycin 100 µg/ml. The medium 
was changed every alternate day; cells 
were harvested and passaged via 
trypsinization at 80 to 90% confluence 
(about 4 days of growth). Cells were also 
grown on collagen coated Transwell 
inserts (12-mm) with transparent 
polyester membranes. Transwell inserts 
were coated with type 1 rat tail collagen 
(100 µg/cm2), equilibrated with medium, 
and seeded at a density of 25,000 
cells/cm2. Following seeding, medium 
was changed every alternate day, and 
transport or uptake studies were 
performed after 5-7 days. 
2.2.2. TRANSPORT STUDIES  
LVR transport was evaluated with 
monolayers of each cell line. All 
transport studies were performed with 
Dulbeco’s modified phosphate-buffered 
saline (DPBS) containing glucose (1 
g/liter) and HEPES (20mM) at pH 7.4. 
LVR and other drug solutions were 
prepared immediately prior to initiating a 
transport study. LVR was dissolved in 
methanol (not exceeding 2% v/v as the 
final concentration) and inhibitors were 
separately dissolved in DMSO (not 
exceeding 2% v/v as the final 
concentration) to prepare a stock solution 
and then diluted with DPBS to the 
specified working concentrations. 
Control solutions also contained the 
same amount of methanol/DMSO as in 
the drug solutions. Volumes of test 
solutions added were 0.5 and 1.5 ml, for 
apical (A) and basolateral (B) chambers 
respectively. Prior to testing, cultured 
monolayers were rinsed and equilibrated 
for 30 min with DPBS. While the drug 
solution was added either in the donor A 
or B chambers, the receiving chamber 
contained only DPBS. Samples (100 µl) 
were withdrawn from the receiving 
chamber at predetermined time points 
(30, 60, 90, 120, 150 and 180 min) and 
replaced with equal volume of DPBS to 
maintain sink conditions. Samples were 
transferred to scintillation vials 
containing 5 ml of scintillation fluid, and 
radioactivity was analyzed using a 
Beckman Scintillation Counter 
(LS6500). All transport studies were 
performed at least in triplicates (n=3) per 
treatment group. Representative results 
are presented for each study. 
2.2.3. DELINEATION OF SPECIFIC 
EFFLUX TRANSPORT 
P-gp mediated transporter function was 
selectively inhibited with P-gp 4008 
(P4), a specific inhibitor of P-gp (Lee et 
al., 2004). For specific experiments, 
GF120918 (GF), a specific inhibitor of P 
glycoprotein and BCRP only, was used 
to inhibit P-gp (Hyafil et al., 1993). GF 
is found to modulate cells expressing 
Pgp and BCRP (de Bruin et al., 1999; 
Wallstab et al., 1999). MRP family 
transporters were selectively inhibited 
with MK-571, a specific leukotriene D4 
(LTD4) receptor antagonist. MK-571, 
specifically inhibits at least MRP1 and 
MRP2, but not P-gp. MK-571 has been 
JIDRJournalofInterdisciplinaryResearch
37
shown to sensitize MRP1- and MRP2-
expressing cell lines  (Gekeler et al., 
1995; van Aubel et al., 1998; Chen et al., 
1999). Specific BCRP efflux inhibitor 
fumitremorgin-C (FC) was used to 
inhibit Bcrp1 mediated transport (Shukla 
et al., 2006). A concentration dependent 
study was performed with increasing 
concentrations of inhibitors, MK-571 in 
MDCKII-MRP2 cells, P4 and GF in 
MDCKII-MDR1 cells and FC in 
MDCKII-Bcrp1 cells, which 
demonstrated maximal inhibition at 100 
µM, 50 µM and 2 µM and 10 µM 
respectively (Tables 3, 4 and 5).  
To chemically inhibit MRPs in 
MDCKII-MRP transfected cell lines, the 
cell monolayers were equilibrated with 
MK-571 (100 µM in transport buffer) for 
30 min prior to initiating an experiment 
to delineate the function of MRPs in 
LVR transport. Similarly, P4 (50 µM) 
and FC (10 ȝM) were added to inhibit P-
gp and Bcrp1 in MDCKII-MDR1 and 
MDCKII-Bcrp1 cells respectively. The 
LVR (0.5 µCi/ml) solutions used in these 
transport studies also contained the 
respective inhibitors.
2.2.4. UPTAKE STUDIES 
2.2.4.1.INHIBITION OF BCRP1-
MEDIATED EFFLUX OF [3H] 
MITOXANTRONE (MX) 
Mitoxantrone is a fluorescent compound 
and a well known BCRP substrate. 
Direct efflux of [3H] MX in MDCKII-
Bcrp1 cells in the presence and absence 
of unlabeled LVR was measured to 
examine whether LVR inhibits Bcrp1-
mediated efflux of [3H] MX. Briefly, 
cells were incubated with [3H] LVR 
(0.5ȝCi/ml) and various concentrations 
of unlabeled LVR (0-25 ȝM) or FC 
(10ȝM), in 1 ml of incubation buffer 
(DPBS pH 7.4.) for 30 min at 37°C. 
Cells were then washed once with ice-
cold PBS, and resuspended in 1 ml of 
incubation buffer for 1 h at 37°C. Efflux 
was terminated by washing once in ice-
cold PBS. The cell pellet was lysed with 
1 ml of 1% SDS and 500 µl of the lysate 
was utilized for scintillation counting. 
Values were normalized to protein 
concentration that was measured using 
the remaining lysate by the modified 
Lowry assay. Intracellular [3H] MX was 
calculated based on the radioactivity 
associated with the cells and expressed 
as picomoles of MX per mg of protein.  
2.3. DATA ANALYSIS 
Linear regression of the amounts 
transported as a function of time yielded 
the rate of transport across the cell 
monolayer (dM/dt). Rate divided by the 
cross-sectional area available for 
transport (Kempf et al.) generated the 
steady state flux as shown in Eq. 1., 
Flux = (dM/dt)/ A Eq. 1 
Permeability was calculated by 
normalizing the steady state flux to the 
donor drug concentration (Cd) according 
to Eq. 2., Permeability = Flux/Cd Eq. 2 
Efflux ratio (ER) was calculated by 
dividing the BL-AP permeability by AP-
BL permeability as shown in Eq.3., 
Efflux ratio = BL-AP permeability/AP-
BL permeability  Eq. 3 
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2.4. STATISTICAL ANALYSIS 
All experiments were conducted at least 
in quadruplicate (n=4) and results are 
expressed as mean r SD. Statistical 
comparison of mean values were 
performed using one-way analysis of 
variance (ANOVA) or Student t test 
(Graph Pad INSTAT, version 3.1). *P < 
0.05 was considered to be statistically 
significant.
3. RESULTS AND DISCUSSION 
3.1.  [3H] LVR transport across the 
MDCKII-WT cell line 
[3H] LVR transport across the MDCKII-
WT cells was determined in the absence 
and presence of various combinations of 
inhibitors. This study enabled us to 
compare the [3H] LVR permeabilities 
across the parental and the transfected 
cell lines in the absence and presence of 
specific efflux inhibitors. LVR 
permeabilities across MDCKII-WT cells 
are summarized in Table 1. Directional 
transport of [3H] LVR across MDCKII-
WT cells in the absence of efflux 
inhibitors was very low (Fig.2a). As a 
result, there was not a significant 
difference in the permeability of [3H] 
LVR in the absence or presence of efflux 
inhibitors (Fig.2b)  in both A and B 
directions as compared to control, 
indicating minimal expressions of efflux 
transporters in MDCKII-WT cells.
Efflux ratios of [3H] LVR in MDCKII-
WT were 1.32 in the absence of any 
inhibitor and 1.10, 1.08, 1.27 and 1.07 in 
the presence of P-gp inhibitor (P4), MRP 
inhibitor (MK), BCRP inhibitor (FC) and 
all the three inhibitors combined 
(P4+FC+MK) respectively (Table 1). 
Therefore, it can be easily concluded 
from this study that a very minimal level 
of active efflux transporters is expressed 
in the MDCKII-WT cell line. 
3.2. [3H] LVR transport across 
MDCKII-MDR1 cells 
LVR permeabilities and the respective 
ERs obtained in the MDCKII-MDR1 
transfected cell line are presented in 
Table 2. MDCKII-MDR1 cells exhibited 
significant directional transport of [3H] 
LVR in the B-A direction.  LVR B-A 
transport was significantly higher (5 
fold) as compared to A-B transport 
(Figs.2c and d). A concentration 
dependent inhibition of LVR transport 
indicated that P4 at 50ȝM concentration 
was optimal for inhibition of P-gp 
mediated efflux in MDCKII-MDR1 
cells. In the presence of P4 (50ȝM), the 
A-B and B-A transport of [3H] LVR was 
almost similar with an ER close to 1.03 
as compared to 4.91 for the control.  This 
apically directed MDR1 transport of 
[3H] LVR was substantially inhibited by 
P-gp inhibitor, P4. We further challenged 
LVR transport with another P-gp 
inhibitor, GF120918, which also inhibits 
BCRP mediated efflux. At 2ȝM
concentration, GF exhibited an ER of 
1.06, a number similar to P4 thereby 
causing a complete blockade of LVR 
efflux.
3.3. [3H] LVR transport across 
MDCKII-MRP2 cells 
LVR permeabilities and the respective 
ERs obtained in the MDCKII-MRP2 
transfected cell line are presented in 
Table 3. MDCKII-MRP2 cells also 
exhibited significant directional transport 
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of [3H] LVR.  B-A transport of [3H] 
LVR was significantly higher (3 fold) 
relative to A-B transport (Figs.2e and f). 
A concentration dependent inhibition of 
LVR transport indicated that 100 ȝM
MK-571 produced complete inhibition of 
MRP mediated efflux. ER for [3H] LVR 
transport was found to be 2.9 in the 
absence of any inhibitor and 1.0 in the 
presence of MK-571 (100 ȝM), a MRP 
inhibitor. Therefore, MK-571 at 100 ȝM
was capable of completely blocking 
apically directed MRP2 mediated 
transport of [3H] LVR.  
3.4.  [3H] LVR transport across 
MDCKII-MRP1 cells 
LVR permeabilities and respective ERs 
obtained in the MDCKII-MRP1 
transfected cell line are noted in Table 4.
MDCKII-MRP1 cells did not exhibit 
significant directional ransport of [3H] 
LVP (Figs.2g and h). ER for [3H] LVR 
transport was found to be 1.26 in the 
absence of any inhibitor, and 1.02 in the 
presence of 100 ȝM MK-571. Although 
the difference in the ER values for LVR 
in the presence and absence of MK-571 
(0.24) are statistically significant, these 
values in MDCKII-MRP1 cells are not 
so significantly different for P-gp (3.88) 
and MRP2 (1.9) cell lines. These results 
indicate that LVR is not a good substrate 
for MRP1.
3.5.  [3H] LVR transport across 
MDCKII-Bcrp1 cells 
LVR permeabilities and respective ERs 
obtained in the MDCKII-Bcrp1 
transfected cell line are summarized in 
Table 5. To determine the optimal 
concentration of FC for inhibition of 
Bcrp1 mediated efflux, a concentration 
dependent transport study was carried 
out with [3H] MX, a classic substrate for 
BCRP efflux pump. At 10ȝM FC 
concentration, MX exhibited an ER of 
1.14 relative to 2.45 for control. Hence, 
this concentration was selected for all 
further inhibition experiments involving 
Bcrp1 mediated efflux. No significant 
directional transport of [3H] LVR was 
observed in MDCKII-Bcrp1 cell 
monolayers (Figs.2i and j). ER values of 
[3H] LVR were 1.08 and 1.17 in the 
absence and in the presence of BCRP 
inhibitor respectively. These values are 
not significantly different suggesting that 
LVR is probably not transported by 
Bcrp1. Also, to confirm our observation 
that LVR is not a substrate for Bcrp1, 
cellular accumulation of [3H] MX was 
measured in MDCKII-Bcrp1 cells in the 
presence of unlabeled LVR and FC 
(Fig.3). Cellular uptake of MX was 
elevated in the presence of BCRP efflux 
inhibitor, but unlabeled LVR did not 
show any competitive uptake with MX. 
Therefore, this data substantiates our 
early conclusion that LVR is not a good 
substrate for Bcrp1.  
3.6. Effects of multidrug resistance 
proteins on [3H] LVR transport
Effects of multidrug resistance proteins 
on [3H] LVR transport across all 
transfected MDCKII cell lines 
(MDCKII-MDR1, MDCKII-MRP2, 
MDCKII-MRP1 and MDCKII-Bcrp1)
were compared with MDCKII-WT cell 
line (Fig.2). MDCK cells form a 
polarized monolayer in which the rate of 
basolaterally or apically directed 
translocation can be measured after 
BothPͲgpandMRP2mediatetransportofLopinavir,aproteaseinhibitor

adding compounds to the A or B side of 
the monolayer. Passive translocation will 
be similar in both directions. Since these 
efflux transporters excrete compounds 
from within the cell to extracellular 
space, the direction of transport will 
depend on the subcellular localization of 
such transporters in polarized cells. Thus 
MRP1, being localized on the basolateral 
membrane should transport in the B 
direction. Conversely MRP2, Bcrp1 and 
P-gp being localized on the apical 
membrane should transport in the apical 
direction. MDCKII-MDR1 and 
MDCKII-MRP2 cells exhibited 
significant directional transport of [3H] 
LVR in the B-A direction (Figs.1c and 
1e) as compared to MDCKII-WT cells, 
indicating that these efflux transporters 
are present on the apical membrane. The 
differences in ER values of [3H] LVR 
transport across MDCKII-WT cells 
(1.32) relative to MDR1 (4.91) and 
MRP2 (2.89) transfected cell lines are 
highly significant. Such differences 
imply an increased efflux of [3H] LVR 
by MDR1 (P-gp) and MRP2 respectively 
due to enhanced expression of these 
transporters in these cell lines. The ER 
values in MDCKII-MDR1 and MDCKII-
MRP2 cell lines were reduced to almost 
1.0 in presence of efflux inhibitors, 
which suggest that LVR is a substrate for 
both P-gp and MRP2 efflux proteins. 
However, MRP1 and Bcrp1 did not 
produce substantial differences in 
directional transport of [3H] LVR 
(Figs.1g and 1i) as compared to 
MDCKII-WT cells, which confirms that 
LVR is not a good substrate for MRP1 
and Bcrp1 efflux transporters. 
Differences in ER values (ER values 
with maximal inhibitory concentrations 
subtracted from the control ER values) 
among MDCKII-MDR1 and MDCKII-
MRP2 cell lines were compared and the 
affinity of LVR for these efflux pumps 
was postulated. These differences were 
1.9 for MRP2 and 3.88 for P-gp. Thus, 
from our studies, it appears that LVR has 
more affinity for P-gp than MRP2.  
4. CONCLUSION 
Our results demonstrate for the first time 
that LVR is extruded from absorptive 
cells by P-gp/MDR1 and MRP2 and this 
efflux can be prevented by specific 
inhibitors such as P4, GF120918 for P-
gp and MK571 for MRP2. This behavior 
was similar to other PIs like SQV, RVR 
and IVR which were also shown to 
interact with P-gp and MRP2 (Huisman 
et al., 2002). LVR did not interact 
significantly with MRP1. P-gp and 
MRP2 are present apically in the 
epithelial cells of intestine, kidney, BBB 
and other tissues which can lead to 
significant efflux of LVR causing 
diminished oral absorption like other PIs 
(Williams and Sinko, 1999). It has been 
reported earlier that several PIs like 
SQV, RVR and nelfinavir (NFV) are 
inhibitors of BCRP efflux transporter 
and amprenavir (APV) and IVR are not 
(Gupta et al., 2004). Our results indicate 
no substantial difference in the ER 
values of LVR in MDCKII-Bcrp1 cells 
in the presence and absence of FC, a 
specific and potent BCRP efflux 
inhibitor. These results clearly indicate 
that LVR is not a substrate of Bcrp1 and 
does not interact with Bcrp1.
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Since specific inhibitors of P-gp and 
MRP2 significantly elevated the 
transport of LVR in the transfected cell 
lines, there is no doubt that these efflux 
transporters may not allow sufficient 
intracellular accumulation of LVR 
thereby reducing anti-HIV efficacy. 
Intestinal P-gp is localised extensively 
on the villus tip of enterocytes (Hunter et 
al., 1993)(i.e., the main site of absorption 
for orally administered compounds 
(Katragadda et al., 2005)). It is, 
therefore, ideally positioned to limit the 
absorption of compounds by pumping 
them back into lumen. Since it is known 
that P-gp limits the oral bioavailability 
and BBB penetration of PIs like SQV, 
NFV and IVR (Kim et al., 1998), it can 
be easily be conceived that P-gp might 
also play an important role in the 
disposition of LVR. Since, MRP2 is also 
now known to localize in the apical 
membrane of polarized cells, it is 
possible that MRP2 also play a 
synergistic role along with P-gp in the 
extrusion of LVR from the cells.
Potential interaction between efflux 
transporters in the gut and CYP3A4 
metabolizing enzymes may be a source 
of variation associated with LVR 
absorption and distribution (Williams 
and Sinko, 1999). In human, CYP3A4 is 
the principal enzyme involved in the 
hepatic and intestinal drug metabolism, 
and there is a striking overlap of 
substrate specificites among CYP3A4, P-
gp and MRPs. The coordinated function 
of both CYP3A and P-gp, MRPs can 
dramatically lower oral bioavailability of 
compounds which are substrates for both 
(van Asperen et al., 1997; Wacher et al., 
1998) and this may also be true for LVR. 
From these results it may be postulated 
that inhibitors of efflux transporters can 
help PIs to achieve therapeutic 
concentrations in blood and sanctuary 
sites like brain and testes. To find a 
single inhibitor which can overcome all 
efflux transporters is not an easy task. 
Use of multiple inhibitors concomitantly 
with LVR for such purpose may lead to 
toxicity. Therefore, prodrug 
derivatization of LVR may be an 
effective strategy to bypass P-gp and 
MRP2 mediated efflux. Our laboratory 
has previously reported that peptide 
prodrug derivatization of SQV such as 
Val-Val-SQV and Gly-Val-SQV can 
enhance transcellular permeability across 
MDCKII-MDR1 cells as compared to 
the parent drug (Jain et al., 2005). These 
prodrugs are taken up by peptide influx 
transporters expressed on the outer 
leaflet of cellular membranes and avoid 
recognition by efflux pumps. Hence, our 
future work would be to design prodrugs 
of LVR enhancing both solubility and 
permeability across gut and BBB. 
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Figure 1: Structure of Lopinavir 
Figure 3: Intracellular accumulation of [3H] MX in MDCKII-Bcrp1 cells
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Figure 2: Transport of [3H] Lopinavir across MDCKII-WT as compared to the transfected 
cell lines of [3H] MX in MDCKII-Bcrp1 cells 
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Permeability and Efflux ratios of 3H LVR across MDCKII-WT cells 
 A-B Permeability
* 106 cm/sec 
B-A Permeability
* 106 cm/sec 
Efflux ratio
Control 4.31 + 0.50 5.70 + 0.49 1.32 
P4 (50ȝM) 5.67 + 0.47 6.28 + 0.61 1.10 
MK571 (100ȝM) 5.29 + 0.48 5.72 + 0.41 1.08 
FC (10ȝM) 4.25 + 0.30 5.39 + 0.14 1.27  
MK571+P4+FC 5.26 + 0.68 5.64 + 0.34 1.07  
ulb LVR 2.5ȝM 3.85 + 0.52 5.02 + 0.44 1.30 
ulb LVR 5ȝM 4.05 + 0.37 4.97 + 0.18 1.23 
ulb LVR 10ȝM 4.96 + 0.20 5.94 + 0.20 1.20 
ulb LVR 25ȝM 5.21 + 0.16 5.82 + 0.52 1.12 
Table 2: 
Permeability and Efflux ratios of 3H LVR across MDCKII-MDR1 cells
 A-B Permeability 
* 106 cm/sec 
B-A Permeability 
* 106 cm/sec 
Efflux ratio 
Control 1.32 + 0.08 6.49 + 0.76 4.91 
P4 (10ȝM) 3.20 + 0.64 4.55 + 0.30 1.40 
P4 (25ȝM) 3.60 + 0.06 4.26 + 0.23 1.18 
P4 (50ȝM) 4.60 + 0.15 4.78 + 0.11 1.03 
GF (0.5ȝM) 4.61 + 0.59 6.70 + 0.51 1.46 
GF (1ȝM) 5.64 + 0.39 7.28 + 0.39 1.25 
GF (2ȝM) 6.32 + 0.45 6.70 + 0.37 1.06 
ulb LVR 2.5ȝM 6.62 + 0.44 8.75 + 0.28 1.32 
ulb LVR 5ȝM 7.90 + 0.41 9.37 + 0.99 1.18 
ulb LVR 10ȝM 6.70 + 0.31 7.85 + 0.23 1.12 
ulb LVR 25ȝM 5.55 + 0.18 6.06 + 0.28 1.09 
Table 3: 
Permeability and Efflux ratios of 3H LVR across MDCKII-MRP2 cells
 A-B Permeability 
* 106 cm/sec 
B-A Permeability 
* 106 cm/sec 
Efflux ratio 
Control 2.32 + 0.13 6.73 + 0.45 2.9 
MK571(50ȝM) 3.08 + 0.14 4.39 + 0.23 1.52 
MK571(100ȝM) 4.89 + 0.28 4.90 + 0.28 1 
MK571(200ȝM) 4.60 + 0.15 4.78 + 0.11 1.02 
ulb LVR 1ȝM 3.45 + 0.26 4.70 + 0.24 1.36 
ulb LVR 2.5ȝM 4.46 + 0.27 5.72 + 0.25 1.23 
ulb LVR 5ȝM 4.49 + 0.20 5.74 + 0.20 1.28 
ulb LVR 10ȝM 4.50 + 0.04 5.22 + 0.31 1.16 
ulb LVR 25ȝM 1.88 + 0.06 2.0 + 0.32 1.09 
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Table 4:
Permeability and Efflux ratios of 3H LVR across MDCKII-MRP1 cells
 A-B Permeability 
* 106 cm/sec 
B-A Permeability 
* 106 cm/sec 
Efflux ratio 
Control 4.54 + 0.27 5.72 + 0.25 1.26 
MK571(50ȝM) 4.71 + 0.14 5.28 + 0.23 1.12 
MK571(100ȝM) 5.09 + 0.28 5.20 + 0.43 1.02 
MK571(200ȝM) 4.97 + 0.52 5.05 + 0.34 1.02 
ulb LVR 2.5ȝM 3.32 + 0.27 4.62 + 0.25 1.40 
ulb LVR 5ȝM 3.45 + 0.26 4.70 + 0.24 1.34 
ulb LVR 10ȝM 4.99 + 0.16 5.74 + 0.26 1.15 
ulb LVR 25ȝM 4.49 + 0.20 5.74 + 0.20 1.08 
Table 5: 
Permeability and Efflux ratios of 3H LVR across MDCKII-Bcrp1 cells 
 A-B Permeability
* 106 cm/sec 
B-A Permeability
* 106 cm/sec 
Efflux ratio 
Control (3H MX) 3.03 + 0.28 7.42 + 0.60 2.45 
FC 1ȝM (3H MX) 5.06 + 0.54 7.59 + 0.79 1.52 
FC 5ȝM (3H MX) 6.00 + 0.58 8.44 + 0.72 1.4 
FC 10ȝM (3H MX) 9.11 + 0.98 7.97 + 0.72 1.14 
Control (3H LVR) 7.64 + 0.91 7.65 + 0.63 1.08 
FC+ MK571+P4 (3H LVR) 8.53 + 0.28 8.42 + 0.60 1.17 
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